259 related articles for article (PubMed ID: 29268716)
1. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
Lakomy R; Poprach A; Bortlicek Z; Melichar B; Chloupkova R; Vyzula R; Zemanova M; Kopeckova K; Svoboda M; Slaby O; Kiss I; Studentova H; Juracek J; Fiala O; Kopecky J; Finek J; Dusek L; Hejduk K; Buchler T
BMC Cancer; 2017 Dec; 17(1):880. PubMed ID: 29268716
[TBL] [Abstract][Full Text] [Related]
2. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
3. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
7. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
9. "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Harrison MR; George DJ; Walker MS; Chen C; Korytowsky B; Kirkendall DT; Stepanski EJ; Abernethy AP
Clin Genitourin Cancer; 2013 Dec; 11(4):441-50. PubMed ID: 23856102
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
[TBL] [Abstract][Full Text] [Related]
11. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
13. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Géczi L; Bodoky G; Rokszin G; Fábián I; Torday L
Pathol Oncol Res; 2020 Oct; 26(4):2201-2207. PubMed ID: 32291570
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
15. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T; Bortlicek Z; Poprach A; Pavlik T; Veskrnova V; Honzirkova M; Zemanova M; Fiala O; Kubackova K; Slaby O; Svoboda M; Vyzula R; Dusek L; Melichar B;
Eur Urol; 2016 Sep; 70(3):469-75. PubMed ID: 26746623
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Pal SK; Signorovitch JE; Reichmann WM; Li N; Koo V; Liu Z; Perez JR; Vogelzang NJ
Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
[TBL] [Abstract][Full Text] [Related]
17. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
18. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
20. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
